Cox-2 inhibitors: still no decisive action.
(1) Evidence that the Cox-2 inhibitors have severe cardiovascular adverse effects continues to accumulate, including an increase in overall mortality in several trials of rofecoxib. (2) Yet regulatory agencies on both sides of the Atlantic have so far only taken half-measures, issuing new contraindications and warnings that complicate matters for prescribers (but not for the companies concerned), and leave patients exposed to significant dangers.
D000544:Alzheimer Disease / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000517:prevention & control; D000075202:Contraindications; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004345:Drug Industry; D005602:France; D033161:Government Regulation; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects; D007783:Lactones / Q000009:adverse effects; D011720:Pyrazoles / Q000009:adverse effects; D018570:Risk Assessment; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D007783:Lactones; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones